ENTX
Price
$2.17
Change
-$0.05 (-2.25%)
Updated
Dec 18, 04:59 PM (EDT)
99 days until earnings call
KALA
Price
$5.85
Change
-$0.34 (-5.49%)
Updated
Dec 18, 04:57 PM (EDT)
Ad is loading...

ENTX vs KALA

Header iconENTX vs KALA Comparison
Open Charts ENTX vs KALABanner chart's image
Entera Bio
Price$2.17
Change-$0.05 (-2.25%)
Volume$300
CapitalizationN/A
Kala BIO
Price$5.85
Change-$0.34 (-5.49%)
Volume$200
CapitalizationN/A
ENTX vs KALA Comparison Chart
Loading...
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTX vs. KALA commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a StrongBuy and KALA is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ENTX: $2.22 vs. KALA: $6.19)
Brand notoriety: ENTX and KALA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 46% vs. KALA: 11%
Market capitalization -- ENTX: $81.77M vs. KALA: $28.54M
ENTX [@Biotechnology] is valued at $81.77M. KALA’s [@Biotechnology] market capitalization is $28.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green whileKALA’s FA Score has 0 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • KALA’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTX is a better buy in the long-term than KALA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 5 TA indicator(s) are bullish while KALA’s TA Score has 3 bullish TA indicator(s).

  • ENTX’s TA Score: 5 bullish, 6 bearish.
  • KALA’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ENTX is a better buy in the short-term than KALA.

Price Growth

ENTX (@Biotechnology) experienced а -3.06% price change this week, while KALA (@Biotechnology) price change was -4.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

ENTX is expected to report earnings on Mar 27, 2025.

KALA is expected to report earnings on May 09, 2023.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTX($79.9M) has a higher market cap than KALA($28.5M). ENTX YTD gains are higher at: 270.000 vs. KALA (-11.571). ENTX has higher annual earnings (EBITDA): -9.16M vs. KALA (-32.84M). KALA has more cash in the bank: 49.2M vs. ENTX (6.92M). ENTX has less debt than KALA: ENTX (309K) vs KALA (37M). ENTX has higher revenues than KALA: ENTX (99K) vs KALA (0).
ENTXKALAENTX / KALA
Capitalization79.9M28.5M280%
EBITDA-9.16M-32.84M28%
Gain YTD270.000-11.571-2,333%
P/E RatioN/AN/A-
Revenue99K0-
Total Cash6.92M49.2M14%
Total Debt309K37M1%
FUNDAMENTALS RATINGS
ENTX vs KALA: Fundamental Ratings
ENTX
KALA
OUTLOOK RATING
1..100
1259
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3757
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALA's Valuation (62) in the Pharmaceuticals Major industry is in the same range as ENTX (84). This means that KALA’s stock grew similarly to ENTX’s over the last 12 months.

KALA's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ENTX (100). This means that KALA’s stock grew similarly to ENTX’s over the last 12 months.

ENTX's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as KALA (100). This means that ENTX’s stock grew similarly to KALA’s over the last 12 months.

ENTX's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as KALA (57). This means that ENTX’s stock grew similarly to KALA’s over the last 12 months.

KALA's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as ENTX (100). This means that KALA’s stock grew similarly to ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTXKALA
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 7 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 20 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WIMI0.880.07
+8.65%
WiMi Hologram Cloud
HRMY33.630.57
+1.72%
Harmony Biosciences Holdings
NVO108.01-0.04
-0.04%
Novo-Nordisk A/S
DGICA16.18-0.20
-1.22%
Donegal Group
LYFT14.01-0.28
-1.96%
Lyft

ENTX and

Correlation & Price change

A.I.dvisor tells us that ENTX and JSPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and JSPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
+2.30%
JSPR - ENTX
32%
Poorly correlated
+4.66%
OPORF - ENTX
31%
Poorly correlated
N/A
IMNM - ENTX
26%
Poorly correlated
-3.38%
TNFA - ENTX
25%
Poorly correlated
+12.84%
CVAC - ENTX
24%
Poorly correlated
-4.84%
More

KALA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALA has been loosely correlated with ATHE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if KALA jumps, then ATHE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALA
1D Price
Change %
KALA100%
+1.31%
ATHE - KALA
36%
Loosely correlated
-1.73%
PALI - KALA
31%
Poorly correlated
+3.26%
ARDX - KALA
28%
Poorly correlated
-13.54%
ENTX - KALA
27%
Poorly correlated
+2.30%
UNCY - KALA
27%
Poorly correlated
-0.07%
More